Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Amprius Technologies, Inc.AMPX · Entity 4742 | Director | June 12, 2026 | June 16, 2026 |
| NVIDIA CORPNVDA · Entity 1023 | Director | June 20, 2008 | June 24, 2008 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Amprius Technologies, Inc.
Report date June 12, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 137,762 |
Reported balance
After 2026-06-12 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-12 · Grant · Acquired 10,423 · Balance 137,762 F1: The securities are represented by restricted stock units. Each restricted stock unit represents the reporting person's right to receive one share of issuer's common stock. 100% of the restricted stock units vest on the earlier of (i) the one-year anniversary of the date the restricted stock units were granted and (ii) the day before the next annual meeting of stockholders, subject to the reporting person's continued service as of the vesting date. F2: Includes 10,423 restricted stock units, each of which represents a contingent right to receive one share of the issuer's common stock, subject to the applicable vesting schedule and conditions of each restricted stock unit. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities are represented by restricted stock units. Each restricted stock unit represents the reporting person's right to receive one share of issuer's common stock. 100% of the restricted stock units vest on the earlier of (i) the one-year anniversary of the date the restricted stock units were granted and (ii) the day before the next annual meeting of stockholders, subject to the reporting person's continued service as of the vesting date.
F2: Includes 10,423 restricted stock units, each of which represents a contingent right to receive one share of the issuer's common stock, subject to the applicable vesting schedule and conditions of each restricted stock unit.
NVIDIA CORP
Report date June 20, 2008 · Filed June 24, 2008
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.76 · Expires 2014-06-19 | Direct | 30,000 |
Reported balance
After 2008-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2008-06-20 · Grant · Acquired 30,000 · Balance 30,000 F1: Automatic grant in connection with service on the Board of Directors. The grant shall begin vesting on the second anniversary of the grant date and thereafter shall vest quarterly over one year, being fully vested in 2011, provided that the Reporting Person has attended at least 75% of the Board of Directors meetings in the two year period following the grant date. If the Reporting Person has not attended at least 75% of the Board of Directors meetings in the two year period following the grant date, the grant shall vest 30% on the third anniversary of the grant date, with the remaining 70% vesting on the fourth anniversary of the grant date. If the Reporting Person's service as a director terminates before the second anniversary of the grant date due to disability, the grant shall immediately vest and become exercisable on a quarterly pro rata basis. If the Reporting Person's service as a director terminates due to death, the grant shall immediately vest and become exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: Automatic grant in connection with service on the Board of Directors. The grant shall begin vesting on the second anniversary of the grant date and thereafter shall vest quarterly over one year, being fully vested in 2011, provided that the Reporting Person has attended at least 75% of the Board of Directors meetings in the two year period following the grant date. If the Reporting Person has not attended at least 75% of the Board of Directors meetings in the two year period following the grant date, the grant shall vest 30% on the third anniversary of the grant date, with the remaining 70% vesting on the fourth anniversary of the grant date. If the Reporting Person's service as a director terminates before the second anniversary of the grant date due to disability, the grant shall immediately vest and become exercisable on a quarterly pro rata basis. If the Reporting Person's service as a director terminates due to death, the grant shall immediately vest and become exercisable.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Zymergen Inc.
Report date October 19, 2022 · Filed October 20, 2022
Section 16 reporting ended · disclosed 2022-10-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-10-19 transaction · row 1
1 source rowRow 1 · 2022-10-19 · Disposition to issuer · Disposed 50,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of July 24, 2022 (the "Merger Agreement"), by and among Ginkgo Bioworks Holdings, Inc. ("Ginkgo"), Pepper Merger Subsidiary Inc. and the Issuer, each share of the Issuer's common stock was cancelled and converted into a right to receive 0.9179 of a share of Class A common stock of Ginkgo (the "Merger Consideration"), together with cash in lieu of any fractional shares of Class A common stock of Ginkgo. Immediately prior to the effective time of the merger (the "Effective Time"), all outstanding Issuer restricted stock units ("RSUs") vested in full pursuant to the terms of the agreements governing such Issuer RSUs. Pursuant to the Merger Agreement, immediately prior to the Effective Time, the Issuer RSUs were cancelled and converted into a right to receive the Merger Consideration in respect of such Issuer RSUs and cash in lieu of any fractional shares of Class A common stock of Ginkgo. |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $10.35 · Expires 2020-12-16 | Direct | 0 |
Reported balance
After 2022-10-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-10-19 · Disposition to issuer · Disposed 33,333 · Balance 0 F2: Immediately prior to the Effective Time, all outstanding Issuer stock options vested in full pursuant to the terms of the agreements governing such stock options. Pursuant to the Merger Agreement, at the Effective Time, each Issuer stock option with an exercise price per share equal to or greater than the Merger Consideration Value (as defined in the Merger Agreement) was cancelled for no consideration. |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $2.70 · Expires 2026-06-24 | Direct | 0 |
Reported balance
After 2022-10-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-10-19 · Disposition to issuer · Disposed 132,333 · Balance 0 F2: Immediately prior to the Effective Time, all outstanding Issuer stock options vested in full pursuant to the terms of the agreements governing such stock options. Pursuant to the Merger Agreement, at the Effective Time, each Issuer stock option with an exercise price per share equal to or greater than the Merger Consideration Value (as defined in the Merger Agreement) was cancelled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of July 24, 2022 (the "Merger Agreement"), by and among Ginkgo Bioworks Holdings, Inc. ("Ginkgo"), Pepper Merger Subsidiary Inc. and the Issuer, each share of the Issuer's common stock was cancelled and converted into a right to receive 0.9179 of a share of Class A common stock of Ginkgo (the "Merger Consideration"), together with cash in lieu of any fractional shares of Class A common stock of Ginkgo. Immediately prior to the effective time of the merger (the "Effective Time"), all outstanding Issuer restricted stock units ("RSUs") vested in full pursuant to the terms of the agreements governing such Issuer RSUs. Pursuant to the Merger Agreement, immediately prior to the Effective Time, the Issuer RSUs were cancelled and converted into a right to receive the Merger Consideration in respect of such Issuer RSUs and cash in lieu of any fractional shares of Class A common stock of Ginkgo.
F2: Immediately prior to the Effective Time, all outstanding Issuer stock options vested in full pursuant to the terms of the agreements governing such stock options. Pursuant to the Merger Agreement, at the Effective Time, each Issuer stock option with an exercise price per share equal to or greater than the Merger Consideration Value (as defined in the Merger Agreement) was cancelled for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 12, 2026 Filed Jun 16, 2026 22:00 UTC | Amprius Technologies, Inc. AMPX · Entity 4742 | GrantCommon stock | 10,423 | $0.00 | $0.00 |
DisclosureSEC source: 0001296381-26-000005 · wk-form4_1781647228.xml · nonDerivative · entry 1 Chu Steven · CIK 0001296381 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,762 F1 · shares: The securities are represented by restricted stock units. Each restricted stock unit represents the reporting person's right to receive one share of issuer's common stock. 100% of the restricted stock units vest on the earlier of (i) the one-year anniversary of the date the restricted stock units were granted and (ii) the day before the next annual meeting of stockholders, subject to the reporting person's continued service as of the vesting date. F2 · balance_after: Includes 10,423 restricted stock units, each of which represents a contingent right to receive one share of the issuer's common stock, subject to the applicable vesting schedule and conditions of each restricted stock unit. Read SEC document |
| March 12, 2026 Filed Mar 12, 2026 23:25 UTC | Amprius Technologies, Inc. AMPX · Entity 4742 | Exercise / conversionStock Option (right to buy) · Derivative | 69,422 | $0.62 Strike: $0.62 | $43,041.64 |
DisclosureSEC source: 0001296381-26-000003 · wk-form4_1773357924.xml · derivative · entry 10 Chu Steven · CIK 0001296381 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 69,422 shares Expires 2027-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 12, 2026 Filed Mar 12, 2026 23:25 UTC | Amprius Technologies, Inc. AMPX · Entity 4742 | Exercise / conversionStock Option (right to buy) · Derivative | 86,143 | $2.61 Strike: $2.61 | $224,833.23 |
DisclosureSEC source: 0001296381-26-000003 · wk-form4_1773357924.xml · derivative · entry 9 Chu Steven · CIK 0001296381 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 184,108 Underlying: Common stock · 86,143 shares Expires 2032-04-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 12, 2026 Filed Mar 12, 2026 23:25 UTC | Amprius Technologies, Inc. AMPX · Entity 4742 | SaleCommon stock | 5,565 | $18.53 | $103,145.05 |
DisclosureSEC source: 0001296381-26-000003 · wk-form4_1773357924.xml · nonDerivative · entry 7 Chu Steven · CIK 0001296381 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 127,339 F5 · price: The price reported in Column 4 is an average execution price. These shares were sold in multiple transactions at prices ranging from $18.50 to $18.61, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F1 · balance_after: Includes 44,444 restricted stock units, each of which represents a contingent right to receive one share of the issuer's common stock, subject to the applicable vesting schedule and conditions of each restricted stock unit. Read SEC document |
| March 12, 2026 Filed Mar 12, 2026 23:25 UTC | Amprius Technologies, Inc. AMPX · Entity 4742 | SaleCommon stock | 50,000 | $18.21 | $910,740.00 |
DisclosureSEC source: 0001296381-26-000003 · wk-form4_1773357924.xml · nonDerivative · entry 6 Chu Steven · CIK 0001296381 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,904 F4 · price: The price reported in Column 4 is an average execution price. These shares were sold in multiple transactions at prices ranging from $18.20 to $18.26, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F1 · balance_after: Includes 44,444 restricted stock units, each of which represents a contingent right to receive one share of the issuer's common stock, subject to the applicable vesting schedule and conditions of each restricted stock unit. Read SEC document |
| March 12, 2026 Filed Mar 12, 2026 23:25 UTC | Amprius Technologies, Inc. AMPX · Entity 4742 | SaleCommon stock | 100,000 | $18.65 | $1,864,670.00 |
DisclosureSEC source: 0001296381-26-000003 · wk-form4_1773357924.xml · nonDerivative · entry 5 Chu Steven · CIK 0001296381 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 182,904 F3 · price: The price reported in Column 4 is an average execution price. These shares were sold in multiple transactions at prices ranging from $18.60 to $18.78, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F1 · balance_after: Includes 44,444 restricted stock units, each of which represents a contingent right to receive one share of the issuer's common stock, subject to the applicable vesting schedule and conditions of each restricted stock unit. Read SEC document |
| March 12, 2026 Filed Mar 12, 2026 23:25 UTC | Amprius Technologies, Inc. AMPX · Entity 4742 | Exercise / conversionCommon stock | 69,422 | $0.62 | $43,041.64 |
DisclosureSEC source: 0001296381-26-000003 · wk-form4_1773357924.xml · nonDerivative · entry 4 Chu Steven · CIK 0001296381 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 282,904 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 44,444 restricted stock units, each of which represents a contingent right to receive one share of the issuer's common stock, subject to the applicable vesting schedule and conditions of each restricted stock unit. Read SEC document |
| March 12, 2026 Filed Mar 12, 2026 23:25 UTC | Amprius Technologies, Inc. AMPX · Entity 4742 | Exercise / conversionCommon stock | 86,143 | $2.61 | $224,833.23 |
DisclosureSEC source: 0001296381-26-000003 · wk-form4_1773357924.xml · nonDerivative · entry 3 Chu Steven · CIK 0001296381 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 213,482 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 44,444 restricted stock units, each of which represents a contingent right to receive one share of the issuer's common stock, subject to the applicable vesting schedule and conditions of each restricted stock unit. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 23:25 UTC | Amprius Technologies, Inc. AMPX · Entity 4742 | Exercise / conversionStock Option (right to buy) · Derivative | 104,132 | $0.62 Strike: $0.62 | $64,561.84 |
DisclosureSEC source: 0001296381-26-000003 · wk-form4_1773357924.xml · derivative · entry 8 Chu Steven · CIK 0001296381 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,422 Underlying: Common stock · 104,132 shares Expires 2027-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 23:25 UTC | Amprius Technologies, Inc. AMPX · Entity 4742 | SaleCommon stock | 166,632 | $17.92 | $2,985,428.90 |
DisclosureSEC source: 0001296381-26-000003 · wk-form4_1773357924.xml · nonDerivative · entry 2 Chu Steven · CIK 0001296381 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 127,339 F2 · price: The price reported in Column 4 is an average execution price. These shares were sold in multiple transactions at prices ranging from $17.90 to $18.00, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F1 · balance_after: Includes 44,444 restricted stock units, each of which represents a contingent right to receive one share of the issuer's common stock, subject to the applicable vesting schedule and conditions of each restricted stock unit. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 23:25 UTC | Amprius Technologies, Inc. AMPX · Entity 4742 | Exercise / conversionCommon stock | 104,132 | $0.62 | $64,561.84 |
DisclosureSEC source: 0001296381-26-000003 · wk-form4_1773357924.xml · nonDerivative · entry 1 Chu Steven · CIK 0001296381 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 293,971 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 44,444 restricted stock units, each of which represents a contingent right to receive one share of the issuer's common stock, subject to the applicable vesting schedule and conditions of each restricted stock unit. Read SEC document |
| June 13, 2025 Filed Jun 18, 2025 00:18 UTC | Amprius Technologies, Inc. AMPX · Entity 4742 | GrantCommon stock | 44,444 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-031974 · wk-form4_1750205879.xml · nonDerivative · entry 1 Chu Steven · CIK 0001296381 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 189,839 F1 · shares: The securities are represented by restricted stock units. Each restricted stock unit represents the reporting person's right to receive one share of issuer's common stock. 100% of the restricted stock units vest on the earlier of (i) the one-year anniversary of the date the restricted stock units were granted and (ii) the day before the next annual meeting of stockholders, subject to the reporting person's continued service as of the vesting date. F2 · balance_after: Includes 44,444 restricted stock units, each of which represents a contingent right to receive one share of the issuer's common stock, subject to the applicable vesting schedule and conditions of each restricted stock unit. Read SEC document |
| October 23, 2024 Filed Oct 25, 2024 22:30 UTC | Amprius Technologies, Inc. AMPX · Entity 4742 | GrantStock Option (right to buy) · Derivative | 173,554 | Not disclosed Strike: $0.62 | Not disclosed |
DisclosureSEC source: 0001628280-24-043851 · wk-form4_1729895395.xml · derivative · entry 2 Chu Steven · CIK 0001296381 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 173,554 Underlying: Common stock · 173,554 shares Expires 2027-12-12 F1 · kind: On October 23, 2024, Amprius, Inc. ("Amprius Holdings") voluntarily liquidated and dissolved and distributed to its stockholders on a pro rata basis an aggregate of 57,195,926 shares of the Issuer's common stock (the "Liquidating Distribution"). In connection with the Liquidating Distribution, the Issuer assumed Amprius Holdings' outstanding options to purchase shares of Amprius Holdings' Class A common stock (the "Holdings Options") granted under the Amprius, Inc. 2008 Stock Plan and the Amprius, Inc. Second Equity Incentive Plan (the "Option Assumption"). As a result of the Option Assumption, each Holdings Option held by the Reporting Person became an option to purchase a number of shares of the Issuer's common stock , subject to certain adjustments to such options to comply with the requirements of U.S. Internal Revenue Code treasury regulation relating to equity grant assumptions. F4 · price: Received in connection with the Option Assumption in exchange for stock options to acquire 250,000 shares of Amprius Holdings' Class A common stock at an exercise price of $0.43 per share. F2 · derivative.exercise_date: The options are fully vested. Read SEC document |
| October 23, 2024 Filed Oct 25, 2024 22:30 UTC | Amprius Technologies, Inc. AMPX · Entity 4742 | GrantStock Option (right to buy) · Derivative | 173,554 | Not disclosed Strike: $0.78 | Not disclosed |
DisclosureSEC source: 0001628280-24-043851 · wk-form4_1729895395.xml · derivative · entry 1 Chu Steven · CIK 0001296381 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 173,554 Underlying: Common stock · 173,554 shares Expires 2034-09-26 F1 · kind: On October 23, 2024, Amprius, Inc. ("Amprius Holdings") voluntarily liquidated and dissolved and distributed to its stockholders on a pro rata basis an aggregate of 57,195,926 shares of the Issuer's common stock (the "Liquidating Distribution"). In connection with the Liquidating Distribution, the Issuer assumed Amprius Holdings' outstanding options to purchase shares of Amprius Holdings' Class A common stock (the "Holdings Options") granted under the Amprius, Inc. 2008 Stock Plan and the Amprius, Inc. Second Equity Incentive Plan (the "Option Assumption"). As a result of the Option Assumption, each Holdings Option held by the Reporting Person became an option to purchase a number of shares of the Issuer's common stock , subject to certain adjustments to such options to comply with the requirements of U.S. Internal Revenue Code treasury regulation relating to equity grant assumptions. F3 · price: Received in connection with the Option Assumption in exchange for stock options to acquire 250,000 shares of Amprius Holdings' Class A common stock at an exercise price of $0.54 per share. F2 · derivative.exercise_date: The options are fully vested. Read SEC document |
| June 07, 2024 Filed Jun 8, 2024 00:44 UTC | Amprius Technologies, Inc. AMPX · Entity 4742 | GrantCommon stock | 125,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-027372 · wk-form4_1717807438.xml · nonDerivative · entry 1 Chu Steven · CIK 0001296381 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 145,395 F1 · shares: The securities are represented by restricted stock units. Each restricted stock unit represents the reporting person's right to receive one share of issuer's common stock. 100% of the restricted stock units vest on the earlier of (i) the one-year anniversary of the date the restricted stock units were granted and (ii) the day before the next annual meeting of stockholders, subject to the reporting person's continued service as of the vesting date. F2 · balance_after: Includes 125,000 restricted stock units, each of which represents a contingent right to receive one share of the issuer's common stock, subject to the applicable vesting schedule and conditions of each restricted stock unit. Read SEC document |
| June 09, 2023 Filed Jun 12, 2023 22:29 UTC | Amprius Technologies, Inc. AMPX · Entity 4742 | GrantCommon stock | 17,895 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-021895 · wf-form4_168660895645462.xml · nonDerivative · entry 1 Chu Steven · CIK 0001296381 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,395 F1 · shares: The securities are represented by restricted stock units. Each restricted stock unit represents the reporting person's right to receive one share of issuer's common stock. 100% of the restricted stock units vest on the earlier of (i) the one-year anniversary of the date the restricted stock units were granted and (ii) the day before the next annual meeting of stockholders, subject to the reporting person's continued service as of the vesting date. F2 · balance_after: Includes 17,895 restricted stock units, each of which represents a contingent right to receive one share of the issuer's common stock, subject to the applicable vesting schedule and conditions of each restricted stock unit. Read SEC document |
| October 19, 2022 Filed Oct 20, 2022 00:15 UTC | Zymergen Inc. ZY · Entity 122955 | Disposition to issuerStock Options · Derivative | 132,333 | $0.00 Strike: $2.70 | $0.00 |
DisclosureSEC source: 0001645842-22-000147 · wf-form4_166622493658190.xml · derivative · entry 3 Chu Steven · CIK 0001296381 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 132,333 shares Expires 2026-06-24 F2 · derivative.exercise_date: Immediately prior to the Effective Time, all outstanding Issuer stock options vested in full pursuant to the terms of the agreements governing such stock options. Pursuant to the Merger Agreement, at the Effective Time, each Issuer stock option with an exercise price per share equal to or greater than the Merger Consideration Value (as defined in the Merger Agreement) was cancelled for no consideration. Read SEC document |
| October 19, 2022 Filed Oct 20, 2022 00:15 UTC | Zymergen Inc. ZY · Entity 122955 | Disposition to issuerStock Options · Derivative | 33,333 | $0.00 Strike: $10.35 | $0.00 |
DisclosureSEC source: 0001645842-22-000147 · wf-form4_166622493658190.xml · derivative · entry 2 Chu Steven · CIK 0001296381 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,333 shares Expires 2020-12-16 F2 · derivative.exercise_date: Immediately prior to the Effective Time, all outstanding Issuer stock options vested in full pursuant to the terms of the agreements governing such stock options. Pursuant to the Merger Agreement, at the Effective Time, each Issuer stock option with an exercise price per share equal to or greater than the Merger Consideration Value (as defined in the Merger Agreement) was cancelled for no consideration. Read SEC document |
| October 19, 2022 Filed Oct 20, 2022 00:15 UTC | Zymergen Inc. ZY · Entity 122955 | Disposition to issuerCommon Stock | 50,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001645842-22-000147 · wf-form4_166622493658190.xml · nonDerivative · entry 1 Chu Steven · CIK 0001296381 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 24, 2022 (the "Merger Agreement"), by and among Ginkgo Bioworks Holdings, Inc. ("Ginkgo"), Pepper Merger Subsidiary Inc. and the Issuer, each share of the Issuer's common stock was cancelled and converted into a right to receive 0.9179 of a share of Class A common stock of Ginkgo (the "Merger Consideration"), together with cash in lieu of any fractional shares of Class A common stock of Ginkgo. Immediately prior to the effective time of the merger (the "Effective Time"), all outstanding Issuer restricted stock units ("RSUs") vested in full pursuant to the terms of the agreements governing such Issuer RSUs. Pursuant to the Merger Agreement, immediately prior to the Effective Time, the Issuer RSUs were cancelled and converted into a right to receive the Merger Consideration in respect of such Issuer RSUs and cash in lieu of any fractional shares of Class A common stock of Ginkgo. Read SEC document |
| September 14, 2022 Filed Sep 16, 2022 23:20 UTC | Amprius Technologies, Inc. AMPX · Entity 4742 | GrantStock Option (right to buy) · Derivative | 270,251 | Not disclosed Strike: $2.61 | Not disclosed |
DisclosureSEC source: 0000899243-22-031394 · doc4.xml · derivative · entry 2 Chu Steven · CIK 0001296381 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,251 Underlying: Common Stock · 270,251 shares Expires 2032-04-13 F2 · price: On September 14, 2022, the Issuer completed a business combination (the "Business Combination") pursuant to the Business Combination Agreement, by and among the Issuer, a wholly owned subsidiary of the Issuer, and Amprius Technologies Operating, Inc. ("Legacy Amprius") At the effective time of the Business Combination (the "Effective Time"), each Legacy Amprius option was converted into an option to purchase a number of shares of Common Stock of the Issuer equal to the product (rounded down to the nearest whole number) of (i) the number of shares of Legacy Amprius common stock subject to the Legacy Amprius option immediately prior to the Effective Time multiplied by (ii) an exchange ratio of approximately 1.45590, at an exercise price per share (rounded up to the nearest whole cent) equal to (A) the exercise price per share of such Legacy Amprius option immediately prior to the Effective Time divided by (B) the Exchange Ratio. F1 · derivative.exercise_date: 1/48 of the total number of shares issuable upon exercise of the option vested on February 1, 2022, and 1/48 of the total number of shares issuable upon exercise of the option vest monthly thereafter until fully vested on January 1, 2026. Read SEC document |
| June 02, 2022 Filed Jun 6, 2022 23:21 UTC | Zymergen Inc. ZY · Entity 122955 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001645842-22-000094 · wf-form4_165455768860954.xml · nonDerivative · entry 1 Chu Steven · CIK 0001296381 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 F1 · shares: Represents restricted stock units that vest in full on the earlier of (a) the first annual anniversary of the date of the grant and (b) immediately prior to the Annual Meeting following the date of grant, subject to Reporting Person's continued service to the Board of Directors through the vesting date. Read SEC document |
| June 20, 2008 Filed Jun 24, 2008 22:14 UTC | NVIDIA CORP NVDA · Entity 1023 | GrantDirector Stock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $19.76 | $0.00 |
DisclosureSEC source: 0001209191-08-038671 · doc4.xml · derivative · entry 1 Chu Steven · CIK 0001296381 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2014-06-19 F1 · derivative.exercise_date: Automatic grant in connection with service on the Board of Directors. The grant shall begin vesting on the second anniversary of the grant date and thereafter shall vest quarterly over one year, being fully vested in 2011, provided that the Reporting Person has attended at least 75% of the Board of Directors meetings in the two year period following the grant date. If the Reporting Person has not attended at least 75% of the Board of Directors meetings in the two year period following the grant date, the grant shall vest 30% on the third anniversary of the grant date, with the remaining 70% vesting on the fourth anniversary of the grant date. If the Reporting Person's service as a director terminates before the second anniversary of the grant date due to disability, the grant shall immediately vest and become exercisable on a quarterly pro rata basis. If the Reporting Person's service as a director terminates due to death, the grant shall immediately vest and become exercisable. Read SEC document |
| June 22, 2007 Filed Jun 26, 2007 22:35 UTC | NVIDIA CORP NVDA · Entity 1023 | GrantDirector Stock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $43.62 | $0.00 |
DisclosureSEC source: 0001243233-07-000009 · edgar.xml · derivative · entry 1 Chu Steven · CIK 0001296381 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2013-06-21 F1 · derivative.exercise_date: Automatic grant in connection with service on the Board of Directors. The grant shall begin vesting on the second anniversary of the grant date and thereafter shall vest quarterly over one year, being fully vested in 2010, provided that the Reporting Person has attended at least 75% of the Board of Directors meetings in the two year period following the grant date. If the Reporting Person has not attended at least 75% of the Board of Directors meetings in the two year period following the grant date, the grant shall vest 30% on the third anniversary of the grant date, with the remaining 70% vesting on the fourth anniversary of the grant date. If the Reporting Person's service as a director terminates before the second anniversary of the grant date due to disability, the grant shall immediately vest and become exercisable on a quarterly pro rata basis. If the Reporting Person's service as a director terminates due to death, the grant shall immediately vest and become exercisable. Read SEC document |
| August 01, 2006 Filed Aug 3, 2006 22:51 UTC | NVIDIA CORP NVDA · Entity 1023 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $22.14 | $0.00 |
DisclosureSEC source: 0001296381-06-000001 · edgar.xml · derivative · entry 1 Chu Steven · CIK 0001296381 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2012-07-31 F1 · derivative.exercise_date: Automatic grant in connection with service on the Board of Directors. The grant shall begin vesting on the second anniversary of the grant date and thereafter shall vest quarterly over one year, being fully vested in 2009, provided that the Reporting Person has attended at least 75% of the Board of Directors meetings in the two year period following the grant date. If the Reporting Person has not attended at least 75% of the Board of Directors meetings in the two year period following the grant date, the grant shall vest 30% on the third anniversary of the grant date, with the remaining 70% vesting on the fourth anniversary of the grant date. If the Reporting Person's service as a director terminates before the second anniversary of the grant date due to disability or death, the grant shall immediately vest and become exercisable on a quarterly pro rata basis. Read SEC document |
| August 01, 2005 Filed Aug 3, 2005 22:05 UTC | NVIDIA CORP NVDA · Entity 1023 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $27.06 | $0.00 |
DisclosureSEC source: 0001296381-05-000001 · edgar.xml · derivative · entry 1 Chu Steven · CIK 0001296381 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2011-07-31 F1 · derivative.exercise_date: Automatic grant in connection with service on the Board of Directors. The grant shall begin vesting on the second anniversary of the grant date and thereafter shall vest quarterly over one year, being fully vested in 2008, provided that the Reporting Person has attended at least 75% of the Board of Directors meetings in the two year period following the grant date. If the Reporting Person has not attended at least 75% of the Board of Directors meetings in the two year period following the grant date, the grant shall vest 30% on the third anniversary of the grant date, with the remaining 70% vesting on the fourth anniversary of the grant date. If the Reporting Person's service as a director terminates before the second anniversary of the grant date due to disability or death, the grant shall immediately vest and become exercisable on a quarterly pro rata basis. F2 · derivative.expiration_date: The six-year life of the option represents a modification to the ten-year life prescribed by the terms of the plan. Read SEC document |
| July 01, 2004 Filed Jul 6, 2004 16:44 UTC | NVIDIA CORP NVDA · Entity 1023 | GrantDirector Stock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $20.47 | $0.00 |
DisclosureSEC source: 0001296381-04-000004 · edgar.xml · derivative · entry 1 Chu Steven · CIK 0001296381 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2010-06-30 F1 · derivative.exercise_date: Non-discretionary grant under NVIDIA's 1998 Non-Employee Directors' Stock Option Plan in connection with the Reporting Person joining the Board of Directors. The option vests quarterly over a three year period beginning 7/1/2004. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.